ATE272072T1 - METHOD FOR PURIFICATION OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST FROM RECOMBINANT E.COLI - Google Patents

METHOD FOR PURIFICATION OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST FROM RECOMBINANT E.COLI

Info

Publication number
ATE272072T1
ATE272072T1 AT97923960T AT97923960T ATE272072T1 AT E272072 T1 ATE272072 T1 AT E272072T1 AT 97923960 T AT97923960 T AT 97923960T AT 97923960 T AT97923960 T AT 97923960T AT E272072 T1 ATE272072 T1 AT E272072T1
Authority
AT
Austria
Prior art keywords
coli
recombinant
value
receptor antagonist
human interleukin
Prior art date
Application number
AT97923960T
Other languages
German (de)
Inventor
Dino Zanette
Edoardo Giacomo Sarubbi
Adolfo Soffientini
Original Assignee
Aventis Bulk S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Bulk S P A filed Critical Aventis Bulk S P A
Application granted granted Critical
Publication of ATE272072T1 publication Critical patent/ATE272072T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Abstract

A process for purifying human Interleukin-1 receptor antagonist (IL-1ra), obtained by fermenting a strain of recombinant E. coli, which comprises: a) loading the mixture to be purified, which has been buffered at a pH value lower than 6.2 and optionally diluted to reduce its ionic strength at a low value, onto a cationic exchange matrix and eluting said matrix with an aqueous buffered solution having a pH value from about 7.5 to 9.0 and a low ionic strength; and b) applying the eluate from the cationic exchange step, containing the desired IL-1ra protein, directly onto an anionic exchange matrix and eluting with an aqueous buffered solution having a pH value within the above range 7.5 to 9.0 and an increased ionic strength.
AT97923960T 1996-06-07 1997-05-21 METHOD FOR PURIFICATION OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST FROM RECOMBINANT E.COLI ATE272072T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96109153 1996-06-07
PCT/EP1997/002591 WO1997047650A1 (en) 1996-06-07 1997-05-21 Process for the purification of human interleukin-1 receptor antagonist from recombinant e. coli

Publications (1)

Publication Number Publication Date
ATE272072T1 true ATE272072T1 (en) 2004-08-15

Family

ID=8222862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923960T ATE272072T1 (en) 1996-06-07 1997-05-21 METHOD FOR PURIFICATION OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST FROM RECOMBINANT E.COLI

Country Status (11)

Country Link
EP (1) EP0938501B1 (en)
JP (1) JP2000512143A (en)
AT (1) ATE272072T1 (en)
AU (1) AU717003B2 (en)
CA (1) CA2257294C (en)
DE (1) DE69730041T2 (en)
DK (1) DK0938501T3 (en)
ES (1) ES2221688T3 (en)
IL (1) IL127155A (en)
PT (1) PT938501E (en)
WO (1) WO1997047650A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927801D0 (en) * 1999-11-24 2000-01-26 Danisco Method
CA2393532A1 (en) * 1999-12-10 2001-06-14 Frank J. Calzone Interleukin-1 receptor antagonist-like molecules and uses thereof
US20080166762A1 (en) * 2006-09-27 2008-07-10 Reliance Life Science Pvt.Ltd. HETEROLOGOUS PRODUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL-1Ra) IN PICHIA PASTORIS
WO2008086811A1 (en) * 2007-01-15 2008-07-24 Upfront Chromatography A/S Production of biofuel and protein from a raw material
DE202007002869U1 (en) 2007-02-27 2008-07-10 Ds Dichtungstechnik Gmbh Sealing ring and push-in joint
SG10201606218WA (en) * 2011-07-29 2016-09-29 Eleven Biotherapeutics Inc Purified Proteins
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
US20210324001A1 (en) 2018-08-29 2021-10-21 Merck Biodevelopment S.A.S. New purification method

Also Published As

Publication number Publication date
EP0938501A1 (en) 1999-09-01
IL127155A0 (en) 1999-09-22
AU2958697A (en) 1998-01-07
CA2257294C (en) 2006-03-14
DE69730041T2 (en) 2005-07-21
WO1997047650A1 (en) 1997-12-18
ES2221688T3 (en) 2005-01-01
AU717003B2 (en) 2000-03-16
EP0938501B1 (en) 2004-07-28
IL127155A (en) 2007-05-15
PT938501E (en) 2004-11-30
DK0938501T3 (en) 2004-11-15
DE69730041D1 (en) 2004-09-02
CA2257294A1 (en) 1997-12-18
JP2000512143A (en) 2000-09-19

Similar Documents

Publication Publication Date Title
US6399333B1 (en) Process for producing erythropoietin containing no animal proteins
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
ATE198482T1 (en) METHOD FOR PRODUCING HIGHLY PURE ALBUMIN
MX9603637A (en) Antibody purification.
EP0134385A3 (en) A protein having cell growth stimulating action, composition thereof and method for producing the same
ATE242317T1 (en) METHOD FOR PURIFYING VIRUSES USING CHROMATOGRAPHY
EP0921818A4 (en) Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
AU3803195A (en) Method for isolation of highly pure von willebrand factor
NZ504752A (en) Hydrophobically-modified protein compositions (particularly hedgehog proteins)
CA2127362A1 (en) Expression and Purification of Recombinant Soluble Tissue Factor
CA2388716A1 (en) Process for the purification of pharmacologically active proteins through cationic exchange chromatography
WO1995009872B1 (en) Dna encoding prostaglandin receptor ip
SE9603068D0 (en) Process for purifying a protein
WO1995000551B1 (en) Prostaglandin receptor fp and dna encoding it
AU656552B2 (en) Process for isolating human albumin from supernatant IV, in particular IV-4, or from COHN's fraction V or from an analogous supernatant or fraction
ATE272072T1 (en) METHOD FOR PURIFICATION OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST FROM RECOMBINANT E.COLI
WO1995019570B1 (en) Antagonists to insulin receptor tyrosine kinase inhibitor
Fahnestock et al. Reconstitution of 50S ribosomal subunits from protein-free ribonucleic acid
ES8200560A1 (en) Homogeneous fibroblast interferon and method for manufacture thereof
EP0087686A3 (en) Homogeneous human immune interferon and process therefor
DE69637154D1 (en) HIGHLY EFFICIENT TISSUE-SPECIFIC SYSTEM FOR THE PREPARATION OF COMPOUNDS USING A STREPTAVIDINE PROTEIN A FUSION PROTEIN
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
Tsuji et al. Charge-reversed, polymer-coated capillary column for the analysis of a recombinant chimeric glycoprotein
WO1995000552B1 (en) Prostaglandin receptor ep3 and dna encoding it
AU7508694A (en) Novel tyrosine kinase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0938501

Country of ref document: EP